| Date | Title | Description |
| 26.08.2026 | Revolutionizing AI Datacenters: Quintessent's Quantum Dot Laser Secures $40 Million | Quintessent secures $40 million Series A. This funding targets AI datacenter optical interconnects. AI requires massive data movement. Existing lasers are power-intensive and scarce. Quintessent's quantum dot comb laser offers a breakthroug... |
| 24.08.2026 | Quintessent Raises $40 Million Series A and Begins Sampling First Product for AI Optical Interconnects | , an innovator in resilient and low-cost AI datacenter optical interconnect products, announced it has raised $40 million in an oversubscribed Series A investment round. Quintessent also announced the start of customer sampling of its singl... |
| 24.08.2026 | Quintessent Raises $40 Million Series A |
SANTA BARBARA, CA, Quintessent, an innovator in resilient and low-cost AI datacenter optical interconnect products, announced it has raised $40 million in an oversubscribed Series A investment round.
>> Click here for more funding da... |
| 24.08.2026 | Quintessent Raises $40M in Series A funding | Quintessent, a Santa Barbara, CA-based provider of AI datacenter optical interconnect products, raised $40M in Series A funding.
The round was led by Cycle Capital with participation from Goldman Sachs XIG-Industry Ventures, Hina Liberty Ca... |
| 24.08.2026 | Quintessent Raises $40 Million Series A As Quantum Dot Laser Targets 40% Lower AI Data Movement Power | Quintessent has raised $40 million in an oversubscribed Series A round while beginning customer sampling of its single-chip quantum dot-based DWDM comb laser for AI data center optical interconnects.
Cycle Capital led the financing, joined ... |
| 20.08.2026 | Remepy Raises $36 Million Series A, Bringing Total Funding To $62 Million As Parkinson’s Hybrid Drug Heads Toward Phase III | Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson’s disease, bringing the company’s total capital raised to $62 million. The round ... |
| 16.08.2026 | Remepy Secures $36 Million Series A, Propelling Hybrid Drug Innovation | Remepy, a New York biotech, secured $36 million in Series A funding. Total raised hits $62 million. O.G. Venture Partners and M Ventures led the round. Funds drive Hybrid Drug development and Parkinson's program, Hybridopa, into global Phas... |
| 12.08.2026 | Remepy Snares $36 Million Series A |
NEW YORK, NY, Remepy, the pioneer of Hybrid Drugs, announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures.
>> Click here for more funding data on Remepy
>> To export Remepy f... |
| 12.08.2026 | Remepy Raises $36M in Series A Funding | Remepy, a NYC-based provider of a platform for hybrid drugs that combine prescription medicines with personalized, AI-driven therapeutic apps, raised $36M in Series A funding.
The round was led by O.G. Venture Partners and M Ventures, with ... |
| 09.07.2026 | Exclusive: Corvic AI launches V5 to turn one-off prompts into repeatable workflows | Enterprise artificial intelligence startup Corvic AI Inc. today released Corvic V5, a version of its platform built around reusing prompts, so when one gets the right answer, V5 can save it as a workflow that fires again on its own and pull... |
| 07.07.2026 | Cyllene Therapeutics Raises €33M in Series C Funding | Cyllene Therapeutics (fka EG 427), a Paris, France-based, company which specializes in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, raised €33M in Series C funding.
GordonMD Global Investments and M Ventures. Existing inv... |
| 06.07.2026 | ReproNovo announces first participant dosed in EU Phase 2 Trial of RPN-002 for Embryo Implantation | - RPN-002 is an orally administered oxytocin receptor antagonist aiming to improve IVF/ICSI success rates
- The NORDIC study marks an important step in advancing ReproNovo’s global Phase 2 pipeline acrossfertility and women’s health, with f... |
| 24.06.2026 | TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation Portfolio | TRIMTECH Therapeutics announced that it has raised an additional $14 million in seed funding, bringing the total round to $47 million.
The additional financing was led by Johnson & Johnson’s corporate venture capital organization, Johns... |
| 23.06.2026 | Trimtech Therapeutics Raises Additional $14M in Seed Funding | Trimtech Therapeutics, a Cambridge, UK-based biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, raised additional $14M in Seed funding.
Back... |
| 28.05.2026 | Loom Ventures: Austrian Construction Giant STRABAG to Invest €100M in InfraTech Startups | Austrian construction giant STRABAG has officially launched its long-awaited corporate venture arm. Under the name Loom Ventures, a new early-stage fund with a volume of 100 million euros is entering the market, focused on European InfraTec... |
| 23.04.2026 | Future Fertility Raises Series A Financing to Scale AI Tools Redefining Fertility Care Worldwide | Future Fertility Leadership Team [from left]: Brian Wu, Kirsten Anwender, Dr. Dan Nayot, Christine Prada, Alex Krivoi, MJ Levitan, Jullin Fjeldstad, Rafael Gonzalez
Future Fertility’s personalized egg quality reports support counselling dis... |
| 24.03.2026 | ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners | What You Should Know
The Funding & The Pivot: ImmuneBridge has secured a $7.7M second seed round (bringing its total seed funding to nearly $20M) led by NFX, with participation from One Way Ventures, M Ventures, Insight Partners, LongGa... |
| 24.12.2025 | FoRx Therapeutics: $50 Million Series A Raised To Advance FORX-428 | FoRx Therapeutics, a clinical-stage biotech developing precision oncology medicines, has closed an insider-led $50 million (CHF 40 million) Series A financing to advance its lead candidate, FORX-428, into and through Phase 1 clinical develo... |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 18.12.2025 | FoRx Therapeutics raises $50 million to advance clinical trials |
Existing investors, including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) ... |
| 18.12.2025 | Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy | Basel-based FoRx Therapeutics, a clinical-stage BioTech company developing precision anti-cancer therapeutics, today announced the close of an insider-led €42 million ($50 million) Series A financing.
Existing investors including EQT Life S... |
| 15.12.2025 | DISCO Pharmaceuticals: €36 Million Seed Funding Raised And Mark Manfredi Named As CEO | DISCO Pharmaceuticals has appointed biotech executive Mark Manfredi, Ph.D., as chief executive officer and completed the final close of a €36 million seed financing round to advance its pipeline of surfaceome-targeted drug candidates for ha... |
| 19.11.2025 | FMC Secures €100M for Advanced Memory Chips | FMC, a German semiconductor firm, has raised €100M to boost its DRAM+ and 3D CACHE+ memory tech. The funding, led by HV Capital and DeepTech & Climate Fonds, will fuel commercialization and global expansion. FMC's chips promise higher e... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 18.11.2025 | FMC Secures $107M to Revolutionize AI Memory Chips | Dresden-based FMC raises $107M to advance its innovative memory chip technology. The funding aims to reduce AI data center energy consumption and challenge global memory chip dominance. FMC's DRAM+ and 3D CACHE+ chips promise faster, more e... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 16.11.2025 | FMC: €100 Million Raised To Advance Next Generation Memory Chips | Semiconductor company FMC has secured €100 million in new capital to accelerate the commercialization of its next-generation DRAM+ and 3D CACHE+ memory technologies as global demand for energy-efficient AI infrastructure continues to grow. ... |
| 14.11.2025 | FMC Raises €100M in Funding | FMC, a Dresden, Germany-based semiconductor company, raised €100m in funding.
The funding included:
€77m in equity coming from a Series C financing round, led by HV Capital and the DeepTech & Climate Fonds (DTCF), along with Vsquared Ve... |
| 14.11.2025 | FMC erhält 100 Millionen – Wolters Kluwer kauft Libra (Kaufpreis: 90 Millionen) | Im #DealMonitor für den 14. November werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor... |
| 13.11.2025 | Germany’s FMC lands €100 million as Europe pushes to reduce reliance on US and Asian memory suppliers | Dresden-based semiconductor innovator FMC has raised €100 million to reduce the energy demand of AI data centres with its sustainable and cost-efficient memory chip – ranking among the largest raise of its kind in the semiconductor industry... |
| 13.11.2025 | FMC raises €100M as it unveils new class of memory chips for the AI era | Semiconductor pioneer FMC has raised €100 million to set new standards in memory chips with its highly innovative technology.
The €77 million in equity comes from FMC's oversubscribed Series C financing round, which is backed by prominent e... |
| 07.10.2025 | Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 | Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025
Tue, Oct 07, 2025 17:00 CET Report this content
Lund, Sweden, 7 October, 2025, Hansa Biopharma AB, “Hansa” (Nasdaq St... |
| 07.10.2025 | 55 North: €134 Million Secured For Quantum Technology Fund | 55 North announced the first close of its inaugural Fund I, having raised €134 million out of a targeted €300 million. This significant milestone establishes 55 North as the largest dedicated venture capital fund focused exclusively on quan... |
| 03.10.2025 | Denmark Unveils World's Largest Quantum Fund, Reshaping Tech Landscape | Denmark's 55 North emerges as the world's largest quantum technology venture fund. It achieved a €134 million first close for its €300 million inaugural fund. Backed by anchor investors EIFO and Novo Holdings, this landmark initiative targe... |
| 02.10.2025 | Denmark launches the world’s largest quantum fund | 55 North, the world's largest dedicated quantum technology venture capital fund, today announced the first close of its €300 million inaugural Fund I at €134 million, establishing its position as the sector's largest pure-play quantum VC.
T... |
| 02.10.2025 | Copenhagen-based 55 North announces €134 million first close for record €300 million quantum technology fund | Copenhagen-based venture capital firm 55 North has announced the first close of its €300 million inaugural fund, raising €134 million with backing from anchor investors Novo Holdings and EIFO (Export and Investment Fund of Denmark). Positio... |
| 08.09.2025 | NRG Therapeutics Secures £50M to Advance Neurodegenerative Disease Therapies | NRG Therapeutics just closed a monumental £50 million Series B financing. This oversubscribed round fuels vital neurodegenerative disease research. The UK-based firm targets mitochondrial dysfunction. Its lead program, NRG5051, aims to trea... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 08.09.2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding.
The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND |
Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases.
The round... |
| 13.08.2025 | NeoLogic raises $10M to develop power-efficient server processors
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | NeoLogic Ltd., a startup that hopes to make processors more efficient by reducing their transistor counts, has raised $10 million in funding.
The company announced the Series A round today. It detailed that KOMPAS VC led the investment with... |
| 14.07.2025 | Actithera Secures $75.5 Million to Propel Precision Radioligand Therapies | Actithera, a cutting-edge biotech firm, recently secured $75.5 million in oversubscribed Series A funding. This significant capital injection powers their precision radioligand therapy (RLT) initiatives. Funds will advance their lead FAP as... |
| 10.07.2025 | Actithera: $75.5 Million Series A Raised For Transforming Precision Radioligand Therapy | Actithera, a biotech company specializing in radiopharmaceuticals, has secured $75.5 million in an oversubscribed Series A financing round. This funding will help advance their lead FAP (Fibroblast Activation Protein) asset into clinical de... |
| 09.07.2025 | Actithera Raises $75.5M in Series A Funding | Actithera, an Oslo, Norway-, and Cambridge, MA-based radiopharmaceutical biotech company developing radioligand therapies (RLTs), raised $75.5M in Series A funding.
The round was led by M Ventures and new investors Hadean Ventures, Sofinnov... |
| 22.05.2025 | ReproNovo's $65 Million Leap: A New Dawn for Reproductive Health | In a world where fertility rates are slipping like sand through fingers, ReproNovo emerges as a beacon of hope. This Swiss HealthTech startup, founded in 2021, has just secured $65 million in Series A financing. The funding round, led by Je... |
| 21.05.2025 | ReproNovo raises USD65 million to advance Phase II clinical trials |
ReproNovo, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company, led by a team with expertise in ... |
| 23.04.2025 | Biolinq's $100 Million Leap: A New Era for Diabetes Management | In the world of health technology, innovation is the lifeblood. Biolinq, a California-based company, has just injected a hefty $100 million into its vision for the future of diabetes management. This Series C funding round, led by Alpha Wav... |
| 22.04.2025 | Biolinq Raises $100M to Expand Biowearable Platform for Metabolic Health | What You Should Know:
– Biolinq, a healthcare technology company focused on developing precision multi-analyte biosensors to improve metabolic health raises $100M in Series C financing round led by Alpha Wave Ventures, with participation fr... |
| 05.03.2025 | TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases | Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding ... |
| 19.11.2024 | IonKraft: Pioneering a Circular Economy in Packaging with €3.5 Million Funding | In a world grappling with plastic waste, innovation shines like a beacon. IonKraft, a startup from Aachen, Germany, has just secured €3.5 million in equity funding. This investment is not just a financial boost; it’s a lifeline for the circ... |
| 18.11.2024 | IonKraft secures €3.5M equity funding to fuel circular economy in packaging. | Aachen-based startup IonKraft has raised an equity financing round of € 3.5M. The round was co-led by M Ventures and TechVision Fund and joined by High-Tech-Gründerfonds. The capital will be used to prepare the market entry and scale produc... |
| 18.11.2024 | Aachen-based IonKraft secures €3.5 million to drive circular economy in packaging | IonKraft GmbH, a startup spun off from RWTH Aachen University in Germany, has closed a €3.5 million first equity funding round.
The round was co-led by M Ventures, the strategic investment arm of Merck, and TechVision Fund (TVF), with parti... |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round |
Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Tue, Jul 16, 2024 09:15 CET Report this content
EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 25.06.2024 | iOnctura's Precision Cancer Treatments Gain Momentum | iOnctura, a clinical-stage biopharmaceutical company based in Amsterdam, recently secured EUR80 million in Series B financing to accelerate the development of their lead asset, roginolisib, for the treatment of uveal melanoma and other onco... |
| 24.06.2024 | iOnctura closes EUR80 million Series B financing |
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with part... |
| 21.05.2024 | UK’s LabGenius secures €40.9M led by Amsterdam’s M Ventures to advance its drug discovery platform | Read this article in:
London-based LabGenius, a drug discovery company, announced that it has secured £35M (approximately €40.96M) in a Series B round of funding. The company specialises in using machine learning to discover new therapeutic... |
| 17.04.2024 | Mosa Meat Secures €40M to Revolutionize Cultivated Beef Market | Mosa Meat, a Dutch cultivated meat company, has secured a whopping €40 million in funding to accelerate its mission of transforming the beef industry. The investment will drive production scale-up, cost reduction, and market entry preparati... |
| 16.04.2024 | Mosa Meat Secures €40M in Funding to Expand Production and Speed Up Launch of Cultivated Meat | 5 Mins Read Dutch cultivated meat pioneer Mosa Meat has raised €40M ($42.4M) in a new funding round to support the “next phase” of the company’s growth, with a public tasting of its burger imminent ahead of its launch in Singapore.
The comp... |
| 16.04.2024 | Maastricht-based Mosa Meat raises €40 million to help bring cultivated beef to consumers | - |
| 05.04.2024 | Nucleai Revolutionizes Clinical Trials with $14M Funding Boost | Nucleai, a pioneer in spatial AI biomarkers, has secured a hefty $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. This investment brings Nucleai's total funding to a solid $60M, fueling their mission to transform ... |
| 04.04.2024 | Chicago AI-based biotech startup Nucleai raises $14 million led by M Ventures | - |
| 03.04.2024 | Nucleai Secures $14M to Enhance Clinical Trial Enrollment with Spatial AI Biomarker | What You Should Know:
– Nucleai, a pioneer in spatial AI biomarkers raises $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA.
– The investment brings Nucleai’s total funding to $60M and fuels their mission to transf... |
| 03.05.2023 | Dutch-based Anavo Therapeutics secures €8.5M to systematically drug phosphatases: Know more | Leiden-based Anavo Therapeutics, a company that claims to be the first to systematically drug phosphatases – a rich target space previously considered undruggable for decades, announced that it has raised €8.5M in a Seed extension round of ... |
| 09.03.2023 | Iktos raises €15.5 million Series A round for AI drug discovery service | French start-up Iktos has raised a €15.5 million Series A round fuelling its launch of its drug discovery platform.
Fresh to the Iktos cap table the round is co-led by M Ventures and Debiopharm Innovation Fund, and includes Omnes Capital.
I... |
| 17.02.2023 | Unisers secures $14M to develop defect-detecting tools in chip-making | |
| 07.07.2022 | Tignis and M Ventures/Merck, KGaA, Darmstadt, Germany Announce Series A Funding for Sustainability in Semiconductor Mfg. | Introductions for Tignis and M Ventures Accelerated through Global Semiconductor Industry Association SEMI Startups for Semiconductor Sustainability Program SEATTLE, WASHINGTON, U.S.A., July 7, 2022 /EINPresswire.com/ -- Tignis, a technolog... |
| 01.04.2022 | Additional $14 million for Altoida to advance its neurocognitive assessment platform | |
| 11.02.2022 | Blazing new frontiers in industrial robotic capabilities, Micropsi raises $30 million | Berlin-based Micropsi has raised $30 million in a Series B funding round. The company produces AI-driven systems for the controlling of industrial robots and enables automation services that previously required the work of humans. The new f... |
| 12.01.2022 | UCLA Spinout PictorLabs Launches with $18.8M to Revolutionize Histopathology | What You Should Know: |
| 11.12.2021 | Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million | Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures |
| 20.09.2021 | Clinical progression and €8M funding for Calypso Biotech | Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 controls immune pathways critically involved in disease onset and maintenance, as well as tissue d... |
| 27.07.2021 | IoT Pioneer Wiliot Secures $200 Million Investment Round Led by SoftBank Vision Fund 2 | With Softbank’s Vision Fund 2 backing, Wiliot will accelerate its mission to create a new era of IoT where intelligence and connectivity are brought to trillions of products that move through global supply chains – from crates, packaging, a... |
| 27.04.2021 | How Merck works with Seeqc to cut through quantum computing hype | Join Transform 2021 this July 12-16. Register for the AI event of the year.
When it comes to grappling with the future of quantum computing, enterprises are scrambling to figure just how seriously they should take this new computing archite... |
| 27.04.2021 | How Merck works with Seeqc to cut through quantum computing hype | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
When it comes to grappling with the future of qua... |
| 09.12.2020 | Mitsubishi joins Mosa Meat’s second Series B close at $20m | Mosa Meat, the Netherlands-based startup that built the world’s first ‘lab-grown’ beef burger back in 2013, has announced a second closing of its Series B round at $20 million.
That takes its total for the round so far to $75 million, follo... |
| 17.10.2020 | TOP 10 FoodTech Startups of Europe | Founders: Greg Orlowski and William Shu |
| 14.10.2020 | Where are the world’s first ‘lab burger’ growers now? Enlarging their Series B raise | These days, it feels like most days are a ‘World Something Day.’ If there’ll ever be an ‘International Cultured Meat Day,’ an apt date to mark it is August 5.
On that day in 2013, Dutch foodtech company Mosa Meat brandished the world’s firs... |
| 14.07.2020 | iOnctura extends series A round to €20 million | |
| 14.07.2020 | iOnctura extends series A round to €20 million | iOnctura SA is a clinical-stage biopharmaceutical company developing a pipeline of next-generation molecules targeting cancer and fibrosis. The company’s lead programme, IOA-244, entered the clinic in Q1 2020 to clinically demonstrate for t... |
| 11.05.2020 | aiCTX changes name to SynSense and closes Series A round | Led by CTC Capital, the latest round included co-investment from several strategic partners, including M Ventures, Ecovacs, and Yunding; and several financial investors, including CAS-Star and Archer Investment. Jade River Capital provides ... |
| 11.05.2020 | aiCTX changes name to SynSense and closes Series A round | |
| 24.01.2020 | Geneva-based biopharma startup raises €15 million | |
| 24.01.2020 | Geneva-based biopharma startup raises €15 million | iOnctura is a clinical-stage biopharmaceutical company founded as a spin-out from Merck, with Merck and Cancer Research UK. The company provides a best-in-class pipeline of molecules that harness both direct and immune-mediated anti-cancer ... |
| 07.01.2020 | Legendairy Foods closes a $4.7M seed round, led by Agronomics and M Ventures | The team around Raffael Wohlgensinger and Britta Winterberg is taking clean dairy production to the next level by combining cutting edge technology with traditional European cheese manufacturing processes. The fresh capital will now be used... |
| 18.06.2019 | A Guide to Germany’s Agtech Ecosystem: Government Support Belies Limited Investor Pool | Europe’s share of global agri-foodtech venture capital is slim. But with growing pressure on food systems to produce more and more sustainably, Europe’s larger economies are ramping up efforts to cultivate a supportive startup scene.
German... |
| 26.02.2019 | String of successes for Merck Serono spin-offs | |
| 23.08.2018 | ApoGen raises additional $4M, adds three biotech vets in pursuit of better cancer treatment | (Bigstock Photo)
Biotech startup ApoGen, which is researching solutions to drug-resistant cancers, is moving into a new phase of development. The company announced Thursday that it has raised an additional $4 million as part of its series A... |
| 18.07.2018 | It Shouldn’t Be Called ‘Clean Meat’ But It Will be Clean, says Cultured Meat’s Founder | “I don’t use the term clean meat for a couple of reasons; it can’t translate into Dutch, French or German, and it kind of suggests that current meat is dirty, which I think unnecessarily criminalizes the meat industry and there’s no need fo... |
| 26.06.2018 | Inthera Bioscience secures €4.7 million in series A financing | |
| 27.03.2018 | Merck KGaA adopts Medisafe medication adherence tool for patients with chronic conditions | Boston and Israeli digital health business Medisafe has inked a deal with Merck KGaA, based in Darmstadt Germany, to roll out customized versions of its mobile medication management and adherence program for drugs taken by people with cardi... |
| 01.03.2017 | Medisafe raises $14.5M and adds London office to reflect growth in Europe | New European investor Octopus Ventures led the Series B with participation from another new backer, M Ventures — the Amsterdam-based, strategic, corporate venture capital arm of Merck KGaA, in Darmstadt, Germany, according to a company news... |
| 01.03.2017 | Medisafe Raises $14.5M in Funding | Medisafe®, the leading personalized medication management platform with over three and a half million patient and caregiver registered users, announced today that it has raised a $14.5M Series B funding round led by Octopus Ventures, and jo... |
| 21.01.2017 | Amazon Alexa Fund, Amgen Ventures among 1K first time digital health investors in 2016 | The report noted that there were more than 1,000 first time investors in digital health companies last year. One frequently hears how so many investors are beginning to move into digital health — so much so that it just becomes another talk... |
| - | Merck KGaA adopts Medisafe medication adherence tool for patients with chronic conditions | Boston and Israeli digital health business Medisafe has inked a deal with Merck KGaA, based in Darmstadt Germany, to roll out customized versions of its mobile medication management and adherence program for drugs taken by people with cardi... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
| - | Blazing new frontiers in industrial robotic capabilities, Micropsi raises $30 million | Berlin-based Micropsi has raised $30 million in a Series B funding round. The company produces AI-driven systems for the controlling of industrial robots and enables automation services that previously required the work of humans. The new f... |
